Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
Dainippon Sumitomo Pharma (DSP) said on May 23 that it will discontinue a global PIII trial for its investigational anticancer drug BBI608 in patients with colorectal cancer following a recommendation from an independent safety monitoring committee. The trial, dubbed CO.23,…
To read the full story
Related Article
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Sumitomo Dainippon Reexamining Midterm Plan Due to Halt of BBI608 Study
August 8, 2014
BUSINESS
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- ASKA’s Relugolix Combo Hits Primary Goal in Japan PIII Fibroid Study
June 23, 2026
- Rege Nephro Raises 1.22 Billion Yen to Advance ADPKD Drug, iPSC Kidney Program
June 23, 2026
- Japan OTC Drug Market Falls for Third Straight Month in May: Intage
June 23, 2026
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…